MX2011008922A - Suspensiones acuosas de riluzol. - Google Patents

Suspensiones acuosas de riluzol.

Info

Publication number
MX2011008922A
MX2011008922A MX2011008922A MX2011008922A MX2011008922A MX 2011008922 A MX2011008922 A MX 2011008922A MX 2011008922 A MX2011008922 A MX 2011008922A MX 2011008922 A MX2011008922 A MX 2011008922A MX 2011008922 A MX2011008922 A MX 2011008922A
Authority
MX
Mexico
Prior art keywords
riluzole
aqueous suspensions
suspensions
riluzole aqueous
devoid
Prior art date
Application number
MX2011008922A
Other languages
English (en)
Inventor
Marco Adami
Paolo Mascagni
Roberta Artico
Daniele Barbareschi
Jaime Moscoso
Tiziano Oldoni
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011008922(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of MX2011008922A publication Critical patent/MX2011008922A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a suspensiones acuosas física y químicamente estables de riluzol, junto con los métodos de manufacturación de las mismas. Tales suspensiones acuosas comprenden riluzol en forma de partículas y al menos un agente humectante, preferiblemente un tensioactivo. El riluzol está en cantidades desde aproximadamente 0.1% hasta aproximadamente 20% en p/v y tiene un tamaño de partícula promedio inferior de 200 mum; tales suspensiones están desprovistas de efectos anestésicos locales conocidos (boca) de riluzol.
MX2011008922A 2009-03-13 2010-03-02 Suspensiones acuosas de riluzol. MX2011008922A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09425101A EP2228054A1 (en) 2009-03-13 2009-03-13 Riluzole aqueous suspensions
PCT/EP2010/052598 WO2010102923A2 (en) 2009-03-13 2010-03-02 Riluzole aqueous suspensions

Publications (1)

Publication Number Publication Date
MX2011008922A true MX2011008922A (es) 2011-12-06

Family

ID=40810549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008922A MX2011008922A (es) 2009-03-13 2010-03-02 Suspensiones acuosas de riluzol.

Country Status (22)

Country Link
US (1) US8765150B2 (es)
EP (2) EP2228054A1 (es)
JP (1) JP5607083B2 (es)
KR (1) KR101680175B1 (es)
CN (1) CN102341091B (es)
BR (1) BRPI1006418A2 (es)
CA (1) CA2748856C (es)
CL (1) CL2011002217A1 (es)
CO (1) CO6410281A2 (es)
CY (1) CY1113825T1 (es)
DK (1) DK2405890T3 (es)
ES (1) ES2400349T3 (es)
HK (1) HK1161985A1 (es)
HR (1) HRP20130021T1 (es)
MX (1) MX2011008922A (es)
PE (1) PE20120649A1 (es)
PL (1) PL2405890T3 (es)
PT (1) PT2405890E (es)
RU (1) RU2498802C2 (es)
SI (1) SI2405890T1 (es)
SM (1) SMT201300022B (es)
WO (1) WO2010102923A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101951220B1 (ko) * 2011-07-13 2019-02-22 싸이토키네틱스, 인코포레이티드 조합 als 치료법
US10357497B2 (en) * 2012-06-23 2019-07-23 Biohaven Pharmaceutical Holding Company Limited Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
EP3023093B1 (en) * 2014-11-20 2017-07-26 S.I.I.T. S.r.l.-Servizio Internazionale Imballaggi Termosaldanti Medicinal preparation based on diosmectite
EP3220890A1 (en) * 2014-11-21 2017-09-27 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
CN107249567B (zh) 2014-11-21 2021-08-03 拜尔哈文制药股份有限公司 利鲁唑的舌下给药
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
CN105726477B (zh) * 2016-03-01 2018-10-12 山东司邦得制药有限公司 一种小儿多潘立酮混悬液及其制备方法
CN108721325B (zh) * 2017-04-13 2020-03-06 辽宁大熊制药有限公司 蒙脱石混悬液及其制备方法
WO2019108594A1 (en) * 2017-11-28 2019-06-06 University Of Houston System Liquid formulations of riluzole for oral and intravenous use
CN111437256A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 一种利鲁唑缓释口服混悬液
CN115025056A (zh) * 2022-06-27 2022-09-09 郑州大学第一附属医院 一种含有替加氟、吉莫斯特和奥替拉西钾的口腔崩解制剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282950B6 (sk) 1990-04-24 2003-01-09 Biota Scientific Management Pty Ltd Deriváty alfa-D-neuramínovej kyseliny, spôsob ich prípravy, ich použitie a farmaceutické prípravky na ich báze
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EP1552831B1 (en) * 1999-06-04 2009-01-07 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for treating multiple sclerosis
CN1306867C (zh) 1999-08-12 2007-03-28 伊莱利利公司 杀外寄生物的Spinosyn水悬浮剂
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6432992B1 (en) 2000-06-05 2002-08-13 Aventis Pharm Sa Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
AU2003290838A1 (en) 2002-11-15 2004-06-15 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
ES2269858T3 (es) * 2003-04-28 2007-04-01 Biofrontera Bioscience Gmbh Utilizacion de riluzol combinado con sustancias auxiliares y aditivos adecuados pra el tratamiento de enfermedades, caracterizadas una hiperproliferacion de queratinocitos, en particular neurodermitis y psoriasis.
US9492541B2 (en) 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20070244056A1 (en) 2004-03-03 2007-10-18 Liat Hayardeny Combination Therapy With Glatiramer Acetate and Riluzole
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
ITMI20061274A1 (it) 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
US9132071B2 (en) * 2006-07-28 2015-09-15 Santen Sas Compositions containing quaternary ammonium compounds
UA41879U (ru) * 2009-02-03 2009-06-10 Сергей Викторович Фурс Инфракрасный обогревательный прибор

Also Published As

Publication number Publication date
CO6410281A2 (es) 2012-03-30
PE20120649A1 (es) 2012-06-07
RU2498802C2 (ru) 2013-11-20
EP2405890B1 (en) 2012-11-28
WO2010102923A3 (en) 2011-03-03
CY1113825T1 (el) 2016-07-27
CA2748856A1 (en) 2010-09-16
KR20120003854A (ko) 2012-01-11
SMT201300022B (it) 2013-03-08
HK1161985A1 (en) 2012-08-17
JP5607083B2 (ja) 2014-10-15
DK2405890T3 (da) 2013-02-04
CN102341091B (zh) 2013-08-07
JP2012520254A (ja) 2012-09-06
US20120039953A1 (en) 2012-02-16
CL2011002217A1 (es) 2012-03-09
EP2228054A1 (en) 2010-09-15
BRPI1006418A2 (pt) 2016-11-29
HRP20130021T1 (hr) 2013-02-28
ES2400349T3 (es) 2013-04-09
WO2010102923A2 (en) 2010-09-16
EP2405890A2 (en) 2012-01-18
PL2405890T3 (pl) 2013-04-30
CN102341091A (zh) 2012-02-01
US8765150B2 (en) 2014-07-01
SI2405890T1 (sl) 2013-02-28
RU2011141422A (ru) 2013-04-20
KR101680175B1 (ko) 2016-11-28
CA2748856C (en) 2017-01-03
PT2405890E (pt) 2013-02-20

Similar Documents

Publication Publication Date Title
MX2011008922A (es) Suspensiones acuosas de riluzol.
MX2011012196A (es) Composiciones y metodos para el suministro de farmaco.
NZ739471A (en) Fertilizer composition and methods of making and using same
MX2020007227A (es) Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa.
MY144999A (en) Method of preparing microfibrillar polysaccharide
PH12015502729A1 (en) Personal care compositions and articles
MX336930B (es) Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
MY165112A (en) Hydrophobised calcium carbonate particles
TW200734090A (en) Method for manufacturing ultrafine silver particle and ultrafine sliver particle obtained by the method
MX352360B (es) Composicion de agente tensioactivo estructurada con ion de metal de tierra alcalina y microfibra de celulosa.
WO2011005440A3 (en) Aggregate particles of titanium dioxide for solar cells
MX2010002062A (es) Composiciones, sistemas, y/o metodos que involucran dioxido de cloro ("cio2").
MX2012004686A (es) Microfibras de celulosa con una distribucion del tamaño de las particulas para composiciones estructuradas de agentes tensioactivos.
MX2013006200A (es) Montaje de acoplamiento para una plataforma rodante y una plataforma rodante.
MX2012013408A (es) Composiciones, sistemas y/o metodos que incluyen dioxido de cloro ("cio2").
TW200730170A (en) Micronised azodicarbonamide, and the preparation and use thereof
CN103695005A (zh) 一种土壤固化剂
GB2487700A (en) Improved silver oxide formulations
MY158490A (en) Manufacture of coated particulate detergents
SG165218A1 (en) Slurry composition and method of fabricating damascene structure using the same
CN108070234A (zh) 一种pc改良剂
CN201916418U (zh) 钢丝绳
CN202068435U (zh) 一种路由器
CN102342294A (zh) 白蜡树防虫剂
CN105368453A (zh) 一种盐碱地改良剂

Legal Events

Date Code Title Description
FG Grant or registration